Endocrine Abstracts

Background: In 1998 the UKPDS study showed that over 10 years of observation there were no significant changes in haemoglobin A1c (HbA1c) in intensive insulin therapy group compared with conventional therapy group. Therefore, we still need new options to treat diabetes. Diabetes mellitus type 2 (DMT2), is one of the MS components. Obesity leads to insulin resistance (IR) and DMT2. Androgen deficiency (AD) is well-known factor to predict the development of diabetes.<p class...

Introduction: Klinefelter syndrome (KS) is the most common sex-chromosome disorder with a prevalence of 1 in every 660 men, but only 25% of the expected number of patients are diagnosed. It is also one of the most common endocrine disorders, and takes the third place after diabetes mellitus and thyroid gland diseases. KS is one of the most frequent causes of hypogonadism in men. It is known that hypogonadism in men has been found to be an independent risk factor for developmen...

Introduction: Underdiagnosis and delayed diagnosis of Klinefelter syndrome (KS) is a major problem. KS is revealed only in 25% of the expected amount of patients. Early diagnosis facilitates prevention of the long-term consequences of hypogonadism and permits to begin testosterone-replacement therapy opportunely. The ‘prototypic’ patient with KS has traditionally been described as tall, thin, with long hips, narrow shoulders, having gynecomastia, small testes, sparse...

Background: The prevalence of TS and other GID, as well as men/women ratio (MWR) of the pathology is the topic of a high interest for professionals in this field. The earlier data from Russia reported the MWR as 1:3 and were different from reported by other countries.Objective: To study the current prevalence of TS and other GID in Russia.Materials and methods: We summarized the data collected in 2006 by four Moscow clinics, experi...

Background: Impaired glycaemic control, resulting in diabetes mellitus type 2 (DMT2), is one of the MS components. In 1998 the UKPDS study showed that over 10 years of observation there were no significant changes in haemoglobin A1c (HbA1c) in intensive insulin therapy group compared with conventional therapy group. Therefore, we still need new options to treat DMT2. Testosterone is well-known for it’s lipolytic activity; obesity leads to insulin resistance and DMT2.<...

Background: For many years testosterone therapy in men was considered to be a risk factor for increasing the PSA level and prostate volume as well as blood count parameters. Objective was to investigate the influence of testosterone therapy on prostate and blood count in men with metabolic syndrome and hypogonadism.Methods: In a randomized, placebo-controlled, double-blind, phase III trial (ClinicalTrials.gov identifier: NCT00696748), 184 men suffering f...

Context: Low testosterone level in men is associated with the metabolic syndrome (MetS) as well as with depressive symptoms, low vitality and sexual dysfunction.Objective: To assess the effects of testosterone administration on these subjective symptoms, which have not extensively been studied in hypogonadal men with the MetS. Design: randomized, placebo-controlled trial. Setting: academic, ambulatory, referral centre. Patients: 184 men suffering from bo...

Background: Metabolic syndrome has a high prevalence in male population, leading to the high rate of cardiovascular disease and mortality. Numerous studies show that low androgen levels in men are associated with the metabolic syndrome. This study tested whether normalization of testosterone levels improves metabolic dysregulations and body composition.Methods: In a randomized, placebo-controlled, double-blind, phase III trial (ClinicalTrials.gov identif...

Background: Numerous studies (among which, studies of androgen deprivation in men with prostate cancer) show that low androgen levels in men are associated with the metabolic syndrome. Obesity and particularly visceral fat excess is associated with pro-thrombotic and pro-inflammatory states as well. This study tested whether normalization of testosterone levels improves markers of inflammation.Methods: In a randomized, placebo-controlled, double-blind, p...

Background: The benefit of testosterone replacement therapy in men with hypogonadism nd metabolic syndrome is known. Safety of testosterone therapy is still a question of a high interest, especially regarding influence on cardiovascular system.Objective: To study the safety of testosterone therapy in hypogonadal men with metabolic syndrome based on cardiac ultrasound data.Methods: We studied 39 men aged 35–69 with hypogonadism...